PHARMA RESEARCH BULLETIN
Open Access Journal (ISSN: 2582-676X)

Review article
Volume 5, Issue 2, 2026, 18-25

Smart Drug Delivery Systems: Responsive Technologies in Pharmacology

Vishal Chanalia[1*], Khushbu[2], Smita Narwal[1], Tekchand[1], Gurpreet Singh[1].

[1] Global Research Institute of Pharmacy, Radaur, Yamuna Nagar-135133, Haryana, India.
[2] Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, 136119, Haryana, India.

* Correspondence: vchanalia7@gmail.com

Received: 14 February 2026; Accepted: 10 June 2026; Published: 30 June 2026

Abstract: Pharmacology is undergoing a technological transformation, increasingly driven by a desire for accuracy and customization in medical care. Conventional drug delivery techniques are limited by nonspecific distribution, require frequent dosing, and pose a significant risk of dose-limiting side effects. Smart drug delivery systems (SDDS) are changing this field by enabling targeted localization and stimuli-triggered release of therapeutic agents. These systems combine developments in materials science—especially in polymers, nanomaterials, and hybrid organic-inorganic platforms—with molecular targeting and real-time sensing technologies to guarantee that drugs are delivered only at the appropriate site, time, and dosage. Intelligent drug delivery systems (SDDS) harness a variety of internal and external stimuli—such as changes in pH, temperature fluctuations, enzymatic activity, redox gradients, exposure to light, application of magnetic fields, and real-time biosensor feedback—to adapt dynamically to evolving physiological and pathological conditions within the body. By accurately regulating drug release triggered by these specific stimuli, smart drug delivery systems (SDDS) aim to significantly improve therapeutic effectiveness while reducing systemic toxicity and harmful side effects. These advanced delivery platforms also support the ongoing shift toward personalized medicine by enabling tailored treatment strategies that respond to individual patient needs and disease profiles. This chapter provides a concise overview of the core principles, enabling technologies, stimulus-responsive mechanisms, clinical applications, current challenges, and future perspectives of smart drug delivery, positioning SDDS at the forefront of innovative next-generation pharmacotherapy.

Keywords: Smart drug delivery system (SDDS), Stimuli-responsive drug delivery, Targeted drug delivery, Nanocarriers, Nanoparticles, Stimuli-sensitive polymers.

1. Introduction

Pharmacology is entering a new era—driven by precision, personalization, and smart technology. Traditional drug delivery methods often suffer from nonspecific distribution, frequent dosing, and significant side effects. The concept of "smart" drug delivery emerged to overcome these limitations by enabling targeted delivery and stimuli-triggered release of drugs at the site of action. Smart drug delivery systems (SDDS) are engineered to respond to specific physiological or externally applied stimuli, ensuring drugs are released only when and where they are needed [1]. These systems bridge the gap between material science, nanotechnology, and pharmacokinetics, offering a dynamic platform for therapeutic innovation. Sensitivity to internal or external bodily signals can be attained through materials (mainly polymers, as well as lipids and metals) that alter their properties based on signal intensity, enabling conversion into modifications in the delivery system that influence its capacity to carry or release a therapeutic agent. Incorporating responsive materials into implantable depots, targetable nanocarriers, and even insertable medical devices can provide activation-controlled and feedback-regulated drug release [2]. Thermo-sensitive controlled-release microcapsules consist of a core layered with water-soluble model drug particles and a thermo-sensitive shell made from nano-sized thermo-responsive hydrogels embedded in an ethylcellulose matrix.

This thermo-sensitive shell exhibits stimuli-responsive drug delivery characteristics, providing a composite system capable of modulating its properties as microcapsules. The integration of stimuli-responsive materials with nanocelluloses and their derivatives (CNF, CMC, HPC, HEC, etc.) holds great promise in drug delivery applications due to their excellent biocompatibility, biodegradability, and responsiveness to stimuli [3]. The field of pharmacology has witnessed remarkable advancements with the emergence of smart drug delivery systems (SDDSs)—innovative platforms that promise a paradigm shift in the way therapeutic agents are administered and controlled within the body. Unlike traditional drug delivery methodologies, which often suffer from systemic side effects, suboptimal dosing, and lack of specificity, SDDSs leverage responsive technologies to achieve precise targeting, controlled release, and improved therapeutic efficacy [4-5]. Responsive drug delivery systems are engineered to sense and respond dynamically to specific internal or external stimuli—such as pH fluctuations, temperature changes, enzymatic activity, light, or magnetic fields—delivering drugs at the right place, time, and dosage. These systems harness advances in materials science, nanotechnology, and biotechnology to design carriers and devices that can adapt to the physiological environment or disease-specific cues, thereby enabling tailored treatment regimens [6-7]. In particular, the application of smart and stimuli-responsive systems holds significant promise for overcoming the limitations of conventional pharmacotherapy, including poor bioavailability, rapid drug clearance, and dose-limiting toxicities [8]. Motivated by the rising need for personalized medicine and the challenge of managing complex diseases such as cancer, autoimmune conditions, and persistent infections, the creation of smart drug delivery systems is leading the way in translational medicine and pharmaceutical advancements [9]. The integration of responsive technologies offers a deeper level of spatiotemporal control, opening new horizons for targeted, non-invasive, and patient-centric therapies. Various smart drug delivery systems are illustrated in **Figure 1**.



Figure 1: Various smart drug delivery systems.

2. Key Principles of Smart Drug Delivery

Smart drug delivery systems operate upon two fundamental and interconnected principles: stimuli-responsiveness and targeted delivery, demonstrated in **Table 1**.

2.1 Stimuli-Responsiveness

At the heart of all SDDS is the capacity to remain quiescent or stable under normal physiological conditions, while being engineered to respond selectively to specific endogenous or exogenous triggers [10]. This responsiveness can be designed into the system at the molecular, material, or device level. Responsiveness confers several advantages (i) On-demand drug release: Releasing the drug only when and where necessary avoids frequent dosing and improves therapeutic precision [11]. (ii) Reduced side effects: By minimizing off-target drug exposure, adverse events are substantially lessened. (iii) Optimized pharmacokinetics: Controlled release profiles can shorten onset times or extend therapeutic action [12].

2.2 Targeted Delivery

Efficient drug delivery is not merely about dosing control, but also about localization. Targeted SDDS exploit molecular recognition (e.g., ligand-receptor interactions, antibody-mediated targeting, passive accumulation in leaky vasculature) so that drugs preferentially accumulate in diseased tissues, such as tumors, inflamed regions, or infected cells [13]. Principle mechanisms include: (i) Passive targeting: Enhanced permeability and retention (EPR) effect in tumors. (ii) Active targeting: Surface modification of carriers with antibodies, peptides, or aptamers for cell-specific delivery. (iii) Subcellular targeting: Directing drugs to mitochondria, nuclei, or other organelles plays a critical role in treating some genetic, infectious, or metabolic diseases [14]. The two pillars—responsive release and targeting—synergistically enhance efficacy and safety, laying the foundation for the broad clinical potential of smart drug delivery [15].

3. Types of Stimuli in Smart Drug Delivery

A defining feature of SDDS is their ability to respond to internal or external stimuli, either inherent to the physiological microenvironment or introduced as part of therapeutic regimens [10, 16]. These can be classified as follows.

3.1 Internal Stimuli (Endogenous Triggers)

Internal stimuli exploit subtle or profound differences between normal and pathological tissues at the microenvironmental level [17].

3.1.1 pH-Responsive Systems

Tissue and subcellular compartments often differ in pH from the surrounding physiological milieu (e.g., tumors: pH 6.4–7.0; inflamed/infected tissue: acidic; lysosomes/endosomes: pH 4.5–6.0) [18]. Carriers (like polymeric micelles or liposomes) are designed to stay stable at physiological pH (~7.4) yet degrade, swell, or discharge their cargo under acidic conditions, ensuring drug activation specifically at the disease site [19].

3.1.2 Enzyme-Responsive Systems

Many diseases are characterized by altered enzyme expression. Matrix metalloproteinases (MMPs) are upregulated in cancer and inflammation; proteases and glycosidases are also often disease-specific [17]. SDDS utilizing enzyme-cleavable linkers or coatings selectively release the drug in response to the overexpressed enzyme [20].

3.1.3 Redox-Responsive Systems

Elevated levels of reduced glutathione (GSH) are commonly found in cancer cells or certain diseased tissues, where they may be 100–1000 times higher than in blood plasma [21]. Redox-responsive SDDS include carriers with disulfide bonds or other redox-labile motifs, which are cleaved in the high-GSH environment, releasing the payload intracellularly [22-23].

3.2 External Stimuli (Exogenous Triggers)

Externally applied stimuli provide an additional or alternative mechanism for user-controlled and spatially-specified drug delivery. UV or near-infrared light breaks photolabile bonds for precise, localized drug release [24]. Magnetic nanoparticles and ultrasound non-invasively trigger drug release for deep-tissue therapy, allowing controlled spatial and temporal delivery [25].

3.2.1 Temperature-Responsive Systems

Polymers such as poly(N-isopropylacrylamide) (PNIPAM) undergo conformational changes at slightly elevated temperatures (e.g., 39–42°C), making them excellent candidates for tumors that are heated locally via hyperthermia [26-27].

3.2.2 Light-Responsive Systems

Light (typically UV or near-infrared) can break photolabile chemical bonds or activate photo-sensitive carriers, causing localized drug release with fine spatial and temporal precision [24]. This enables highly controllable,

spatially and temporally precise drug delivery, often used in superficial tumors or when deep penetration by NIR light is feasible

3.2.3 Magnetic and Ultrasound-Responsive Systems

Magnetic nanoparticles can be heated via oscillating magnetic fields, promoting active drug release ("magneto-thermal therapy") [25]. Ultrasound waves, meanwhile, can trigger drug release by disrupting carrier stability or inducing cavitation effects. These approaches enable deep-tissue, non-invasive activation of SDDS [28].

Table 1. Major Stimuli Types and Representative SDDS Designs

Sr. No.	Stimulus Type	Biological or Applied Signal	Example Carrier/System	Application/Benefit	Ref.
1.	pH	Acidic tumor, infection, lysosome	Polymeric micelle, liposome	Tumor/infection selectivity	[19]
2.	Enzyme	MMPs, proteases, glycosidases	Peptide-linker conjugates	Cancer/inflammation selectivity	[20]
3.	Redox	High GSH (tumor, intracellular)	Disulfide-crosslinked nanoparticles	Intracellular cytotoxic drug release	[22-23]
4.	Temperature	Local hyperthermia	PNIPAM-based hydrogel/micelle	Thermo-triggered tumor therapy	[27]
5.	Light	UV/NIR irradiation	Photolabile polymer-liposomes	Temporal/spatial precision	[24]
6.	Magnetic/Ultrasound	External magnetic field/ultrasound	Magnetic liposomes/nanoparticles	Deep-tissue, non-invasive release	[28]

4. Technologies Enabling Smart Drug Delivery

Rapid progress in material science and nanotechnology has led to a diverse toolbox of platforms for responsive drug delivery.

4.1 Nanoparticles and Nanocarriers

Nanoparticulate carriers offer many advantages for drug delivery: large surface area, functionalizable surfaces, and tunable core/shell architecture [29]. Classes of nanocarriers include:

4.1.1 Liposomes

Spherical vesicles with a phospholipid bilayer; can carry hydrophilic and hydrophobic drugs and be PEGylated or ligand-conjugated for enhanced targeting [30].

4.1.2 Polymeric nanoparticles/micelles

Biodegradable synthetic or natural polymers (e.g., PLGA, chitosan, PEG, poly(N-isopropylacrylamide)), sometimes responsive to pH, temperature, or enzymes [31].

4.1.2 Dendrimers

Tree-like, multibranched molecules, extensively functionalizable for drug conjugation and stimuli-responsiveness [32].

4.1.3 Magnetic, gold, or silica nanoparticles

Enable magnetic or optical responsiveness and can be loaded with drugs or imaging agents [33]. Nanocarrier surfaces can be functionalized with ligands, aptamers, or antibodies for targeting, or with stimuli-cleavable linkers for controlled release [34].

4.2 Hydrogels

Hydrogels are highly hydrated, porous networks typically formed from synthetic or natural polymers (polyvinyl alcohol, alginate, chitosan, cellulose derivatives). Their high drug loading capacity and sensitivity to environmental triggers (pH, temperature, glucose, light, etc.) make them versatile carriers for localized or sustained release, especially in tissue engineering and wound healing [35]

4.3 Microneedles and Implantable Devices

4.3.1 Microneedle Arrays

Microneedle arrays are minimally invasive, pain-free platforms that breach the outermost skin layer to deliver drugs or vaccines directly into the dermis. Integration of stimuli-responsive polymers or miniaturized reservoirs enables both passive sustained and triggered ("on-demand") release [36-37].

4.3.2 Implantable Devices

These, including smart pumps or chips, can incorporate biosensors and microprocessors to enable real-time feedback, dose titration, and wireless or programmed control. These devices are being developed for chronic diseases such as diabetes, chronic pain, and certain cancers [38-39].

5. Applications in Therapeutics

Smart drug delivery is catalyzing fresh possibilities in the design, precision, and efficacy of pharmacological therapies. Notable clinical and translational applications include:

5.1 Oncology

SDDS have perhaps found their greatest traction in cancer therapy, where the need for extraordinary localization and highly controlled release is paramount to avoid toxicity. Tumor tissues often show increased enzyme activity, abnormal vasculature (EPR effect), and acidic pH. Responsive systems (e.g., pH-sensitive micelles, enzyme-responsive nanoparticles) exploit these features for selective cytotoxic drug delivery [40]. The integration of magnetic or photo-responsive carriers can enable externally triggered, localized tumor ablation [41-42].

5.2 Diabetes

A transformative target for SDDS, glucose-responsive insulin delivery systems employ glucose oxidase or other sensor-enzymes to detect changes in blood glucose and activate release accordingly [43]. These systems—formulated as hydrogels, microneedle patches, or implantable reservoirs—mimic the function of pancreatic beta cells and greatly reduce the risk of hypo/hyperglycemia [44-45].

5.3 Neurodegenerative Disorders

Penetrating the blood-brain barrier (BBB) continues to be a significant obstacle in CNS drug delivery. SDDS formulations-including ligand-targeted nanoparticles, transferrin- or lactoferrin-conjugated liposomes, and peptide-modified hydrogels—show promise for delivering drugs across the BBB in diseases such as Alzheimer's and Parkinson's. Responsive systems can be activated by brain pH, enzymes, or redox environment to release therapeutics intracellularly [46-47].

5.4 Infectious Diseases

In chronic or deep-seated infections, the need for site-specific and sustained antibiotic/antimicrobial delivery is acute. Responsive hydrogels and nanocarriers can be activated by local infection-associated enzymes, pH, or oxidative burst, ensuring concentrated drug levels and limiting resistance [48]. Microneedle patches for vaccine and antibacterial delivery are also being developed [37].

5.5 Autoimmune and Inflammatory Disorders

SDDS are being explored for rheumatological and inflammatory bowel diseases to reduce systemic immunosuppression by targeting inflamed tissue and releasing biologics, steroids, or cytokine blockers in response to local triggers (*e.g.*, cytokine, ROS, pH) [49].

6. Challenges and Limitations

Despite the remarkable advancements and potential of smart drug delivery systems, several significant scientific and practical challenges remain. The complexity involved in designing and manufacturing multi-responsive, multi-targeted systems makes scaling up production and ensuring consistent quality difficult. Achieving stability and reproducibility during manufacturing is an ongoing obstacle. Biocompatibility and safety also present major concerns, as some highly functional materials, including cationic polymers and inorganic nanoparticles, may trigger immune responses or toxicity, necessitating thorough preclinical evaluation [50]. Additionally, optimizing pharmacokinetics and biodistribution is challenging, with issues such as rapid clearance by the kidneys, liver, or immune system and limited bioavailability at target sites [51]. Clinical adoption of these systems is further hampered by a lack of standardized regulatory frameworks and the substantial safety and efficacy evidence required for approval. Lastly, while innovations like microneedles may enhance patient comfort and compliance, patient acceptance of new devices or nanotechnology-based systems can be variable, presenting another obstacle to widespread implementation [52].

7. Future Perspectives

Advances in artificial intelligence, biosensor technology, and nanofabrication are poised to further transform SDDS. Integration of closed-loop feedback systems, capable of real-time monitoring of disease biomarkers and automatic drug titration, is underway, supported by ultra-miniaturized sensors and wireless control. Personalized SDDS, tailored via 3D-printed or biofabricated devices to individual patient anatomy or biomarker profiles, are becoming feasible. Multi-functional, multi-responsive carriers capable not only of therapy but also of diagnosis (theranostics) and monitoring represent a future standard. Collaborative cross-disciplinary research involving material scientists, pharmacologists, engineers, clinicians, and regulatory scientists will be essential to realize the full clinical and societal potential of SDDS.

8. Conclusion

The development of smart drug delivery systems marks a paradigm shift in pharmacology, heralding an era where therapeutic agents are delivered with unprecedented precision, adaptability, and patient specificity. As research and development in materials science, nanotechnology, and device engineering continue apace, SDDS are set to become an integral element of personalized medicine—transforming passive drug carriers into responsive, interactive platforms that adapt to disease dynamics and individual patient needs. While significant challenges remain, ongoing interdisciplinary advances will likely cement SDDS as cornerstones of future therapeutics, benefiting millions through safer, more effective, and patient-centric therapies.

9. References

1. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153(3):198-205.
2. Alvarez-Lorenzo C, Concheiro A. Smart drug delivery systems: from fundamentals to the clinic. Chem Commun (Camb). 2014;50(58):7743-7765.
3. Xie J, Li J. Smart drug delivery system based on nanocelluloses. J Bioresour Bioprod. 2017;2(1):1-3.
4. Rana A, Adhikary M, Singh PK, Das BC, Bhatnagar S. “Smart” drug delivery: a window to future of translational medicine. Front Chem. 2023;10:1095598.
5. Liu D, Yang F, Xiong F, Gu N. The smart drug delivery system and its clinical potential. Theranostics. 2016;6(9):1306-1323.
6. Yu H, Gao R, Liu Y, Fu L, Zhou J, Li L. Stimulus-responsive hydrogels as drug delivery systems for inflammation targeted therapy. Adv Sci (Weinh). 2024;11(1):e2306152.
7. Bruschi ML, Borghi-Pangoni FB, Junqueira MV, de Souza Ferreira SB, da Silva JB. Environmentally responsive systems for drug delivery. Recent Pat Drug Deliv Formul. 2017;11(2):89-100.
8. Boppana SH, Kutikuppala LVS, Sharma S, C M, Rangari G, Misra AK, Kandi V, Mishra S, Singh PK, Rabaan AA, Mohapatra RK, Kudrat-E-Zahan M. Current approaches in smart nano-inspired drug delivery: a narrative review. Health Sci Rep. 2024;7(4):e2065.
9. Kallepalli B, Garg U, Jain N, Nagpal R, Malhotra S, Tiwari T, Kaul S, Nagaich U. Intelligent drug delivery: pioneering stimuli-responsive systems to revolutionize disease management-an in-depth exploration. Curr Drug Deliv. 2025;22(2):195-214.

10. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.
11. Sun T, Dasgupta A, Zhao Z, Nurunnabi M, Mitragotri S. Physical triggering strategies for drug delivery. Adv Drug Deliv Rev. 2020;158:36-62.
12. Karimi M, Ghasemi A, Sahandi Zangabad P, Rahighi R, Moosavi Basri SM, Mirshekari H, Amiri M, Shafaei Pishabad Z, Aslani A, Bozorgomid M, Ghosh D, Beyzavi A, Vaseghi A, Aref AR, Haghani L, Bahrami S, Hamblin MR. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457-1501.
13. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71-79.
14. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.
15. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
16. Timko BP, Dvir T, Kohane DS. Remotely triggerable drug delivery systems. Adv Mater. 2010;22(44):4925-4943.
17. Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale. 2014;6(21):12273-12286.
18. Tehrani Fateh S, Moradi L, Kohan E, Hamblin MR, Shiralizadeh Dezfuli A. Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications. Beilstein J Nanotechnol. 2021;12:808-862.
19. Ding H, Tan P, Fu S, Tian X, Zhang H, Ma X, Gu Z, Luo K. Preparation and application of pH-responsive drug delivery systems. J Control Release. 2022;348:206-238.
20. Sun Y, Davis E. Nanoplatforms for targeted stimuli-responsive drug delivery: a review of platform materials and stimuli-responsive release and targeting mechanisms. Nanomaterials (Basel). 2021;11(3):746.
21. Li S, Saw PE, Lin C, Nie Y, Tao W, Farokhzad OC, Zhang L, Xu X. Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy. Biomaterials. 2020;234:119760.
22. Luo Y, Yin X, Yin X, Chen A, Zhao L, Zhang G, Liao W, Huang X, Li J, Zhang CY. Dual pH/redox-responsive mixed polymeric micelles for anticancer drug delivery and controlled release. Pharmaceutics. 2019;11(4):176.
23. Ghorbani M, Hamishehkar H. Redox-responsive smart nanogels for intracellular targeting of therapeutic agents: applications and recent advances. J Drug Target. 2019;27(4):408-422.
24. Tao Y, Chan HF, Shi B, Li M, Leong KW. Light: a magical tool for controlled drug delivery. Adv Funct Mater. 2020;30(49):2005029.
25. Han Z, Liu G. CEST MRI trackable nanoparticle drug delivery systems. Biomed Mater. 2021;16(2):024103.
26. Luo J, Zhao X, Guo B, Han Y. Preparation, thermal response mechanisms and biomedical applications of thermosensitive hydrogels for drug delivery. Expert Opin Drug Deliv. 2023;20(5):641-672.
27. Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev. 2006;58(15):1655-1670.
28. Moradi Kashkooli F, Jakhmola A, Hornsby TK, Tavakkoli JJ, Kolios MC. Ultrasound-mediated nano drug delivery for treating cancer: fundamental physics to future directions. J Control Release. 2023;355:552-578.
29. Karimi M, Ghasemi A, Sahandi Zangabad P, Rahighi R, Moosavi Basri SM, Mirshekari H, Amiri M, Shafaei Pishabad Z, Aslani A, Bozorgomid M, Ghosh D, Beyzavi A, Vaseghi A, Aref AR, Haghani L, Bahrami S, Hamblin MR. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457-1501.
30. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
31. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8(6):2101-2141.
32. Huang D, Wu D. Biodegradable dendrimers for drug delivery. Mater Sci Eng C Mater Biol Appl. 2018;90:713-727.
33. Huang H, Liu R, Yang J, Dai J, Fan S, Pi J, Wei Y, Guo X. Gold nanoparticles: construction for drug delivery and application in cancer immunotherapy. Pharmaceutics. 2023;15(7):1868.

34. Hossen S, Hossain MK, Basher MK, Mia MNH, Rahman MT, Uddin MJ. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J Adv Res. 2019;15:1-18.
35. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1(12):16071.
36. Larrañeta E, McCrudden MT, Courtenay AJ, Donnelly RF. Microneedles: a new frontier in nanomedicine delivery. Pharm Res. 2016;33(5):1055-1073.
37. Avcil M, Çelik A. Microneedles in drug delivery: progress and challenges. Micromachines (Basel). 2021;12(11):1321.
38. Santini JT Jr, Cima MJ, Langer R. A controlled-release microchip. Nature. 1999;397(6717):335-338.
39. Ita K. Transdermal delivery of drugs with microneedles-potential and challenges. Pharmaceutics. 2015;7(3):90-105.
40. Li M, Zhao G, Su WK, Shuai Q. Enzyme-responsive nanoparticles for anti-tumor drug delivery. Front Chem. 2020;8:647.
41. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
42. Karimi M, Ghasemi A, Sahandi Zangabad P, Rahighi R, Moosavi Basri SM, Mirshekari H, Amiri M, Shafaei Pishabad Z, Aslani A, Bozorgomid M, Ghosh D, Beyzavi A, Vaseghi A, Aref AR, Haghani L, Bahrami S, Hamblin MR. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457-1501.
43. Zhou X, Chen S, Pich A, He C. Advanced bioresponsive drug delivery systems for promoting diabetic vascularized bone regeneration. ACS Biomater Sci Eng. 2025;11(1):182-207.
44. Wang J, Wang Z, Yu J, Kahkoska AR, Buse JB, Gu Z. Glucose-responsive insulin and delivery systems: innovation and translation. Adv Mater. 2020;32(13):e1902004.
45. Liu J, Yi X, Zhang J, Yao Y, Panichayupakaranant P, Chen H. Recent advances in the drugs and glucose-responsive drug delivery systems for the treatment of diabetes: a systematic review. Pharmaceutics. 2024;16(10):1343.
46. Bhunia S, Kolishetti N, Vashist A, Yndart Arias A, Brooks D, Nair M. Drug delivery to the brain: recent advances and unmet challenges. Pharmaceutics. 2023;15(12):2658.
47. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34-47.
48. Wells CM, Harris M, Choi L, Murali VP, Guerra FD, Jennings JA. Stimuli-responsive drug release from smart polymers. J Funct Biomater. 2019;10(3):34.
49. Liu J, Li Y, Chen S, Lin Y, Lai H, Chen B, Chen T. Biomedical application of reactive oxygen species-responsive nanocarriers in cancer, inflammation, and neurodegenerative diseases. Front Chem. 2020;8:838.
50. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4):487-495.
51. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4):487-495.
52. Nair A, Greeny A, Nandan A, Sah RK, Jose A, Dyawanapelly S, Junnuthula V, K V A, Sadanandan P. Advanced drug delivery and therapeutic strategies for tuberculosis treatment. J Nanobiotechnology. 2023;21(1):414.

How to cite this article: Chanalia V, Khushbu, Narwal S, Tekchand, Singh G. Smart Drug Delivery Systems: Responsive Technologies in Pharmacology. Pharm Res Bull. 2026;5(2):18-25.